Meanwell C A, Blake A E, Kelly K A, Honigsberger L, Blackledge G
Eur J Cancer Clin Oncol. 1986 Jul;22(7):815-9. doi: 10.1016/0277-5379(86)90368-8.
Ifosfamide and mesna were administered to 77 patients with advanced malignancies. Seven (9%) experienced a severe but reversible encephalopathy. In 56% of patients in whom EEG data was available, characteristic changes were seen with or without mild clinical toxicity. Discriminant analysis identified low serum albumin concentration, high serum creatinine concentration and the presence of pelvic disease as variables which predispose patients to the development of severe encephalopathy. A nomogram has been constructed which can be used to determine the probability that an individual patient may be given ifosfamide and mesna safely. This has important implications for the clinical use of a highly active chemotherapy regimen.
对77例晚期恶性肿瘤患者给予异环磷酰胺和美司钠治疗。7例（9%）出现严重但可逆的脑病。在有脑电图数据的患者中，56%出现了特征性改变，无论有无轻度临床毒性。判别分析确定低血清白蛋白浓度、高血清肌酐浓度和盆腔疾病的存在为使患者易发生严重脑病的变量。已构建了一个列线图，可用于确定个体患者安全使用异环磷酰胺和美司钠的概率。这对一种高活性化疗方案的临床应用具有重要意义。
